Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Summit Global Investments

Summit Global Investments boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 75.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 729,200 shares of the company's stock after purchasing an additional 313,642 shares during the period. Summit Global Investments' holdings in Takeda Pharmaceutical were worth $9,655,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Pathstone Holdings LLC lifted its holdings in shares of Takeda Pharmaceutical by 1.0% in the 3rd quarter. Pathstone Holdings LLC now owns 430,676 shares of the company's stock valued at $6,124,000 after buying an additional 4,280 shares during the period. Caprock Group LLC grew its stake in shares of Takeda Pharmaceutical by 7.7% during the 3rd quarter. Caprock Group LLC now owns 34,304 shares of the company's stock worth $488,000 after purchasing an additional 2,454 shares during the period. Advisors Asset Management Inc. boosted its holdings in Takeda Pharmaceutical by 41.4% during the third quarter. Advisors Asset Management Inc. now owns 51,226 shares of the company's stock worth $728,000 after buying an additional 14,992 shares in the last quarter. Smithfield Trust Co grew its position in Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock worth $49,000 after buying an additional 1,490 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Takeda Pharmaceutical by 17.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 187,165 shares of the company's stock valued at $2,661,000 after buying an additional 27,628 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Remove Ads

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK traded up $0.06 during trading on Tuesday, hitting $15.07. 432,091 shares of the stock were exchanged, compared to its average volume of 1,761,527. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.31. The company has a market cap of $47.94 billion, a PE ratio of 37.66, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a fifty day moving average price of $14.00 and a two-hundred day moving average price of $13.91. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.